What Is Retatrutide? How It Actually Works

Why Retatrutide Makes You Hungrier Than Semaglutide or Tirzepatide

One of the biggest problems with switching from semaglutide or tirzepatide to retatrutide is that appetite suppression isn't nearly as strong. The food noise comes back and people assume the dose is wrong. What they don't realize is that retatrutide is actually the weakest at suppressing your appetite out of all three of these compounds, and that was a design choice.

retatrutide activates three receptors, GLP-1, GIP, and glucagon, and that triple-agonist design is what the entire phase 3 TRIUMPH program is built around (Giblin 2026). When you ask one molecule to hit three targets, the chemistry forces you to trade potency at one for potency at another.

They made retatrutide about nine times more potent at GIP, but only 40% as potent at GLP-1. And GLP-1 is the receptor responsible for appetite suppression. And that's why your hunger feels stronger when you're on retatrutide versus the other two.

What you bought with that trade is the glucagon arm. Glucagon raises energy expenditure and pulls fat out of the liver (McGlone 2024). So what happens when you start retatrutide is your liver turns into this furnace that's constantly burning calories even at rest.

Liver fat oxidation isn't something you can sense while it's happening, since there are no nerve endings reporting on it to your brain, but hunger registers instantly and impossible to ignore. So the experience of the drug underreports what it is doing, which is why people quit it for the wrong reason.

That said, hunger does come down on retatrutide. In a phase 2 study in adults with type 2 diabetes, participants reported less hunger and less tendency to overeat, and those changes tracked with how much weight they lost (Kanu 2025). It is weaker than what a semaglutide user is used to, not absent.

But if you understand why that trade-off was made and you still need help with food noise, there's a peptide that can help, and understanding why it works differently matters more than just knowing it exists.

Your pancreas releases a hormone called amylin alongside insulin every time you eat, and that hormone's job is to signal your brain that you've had enough and should stop eating. As insulin resistance builds, amylin stays elevated, the receptors downregulate, and the signal stops landing even though your body keeps sending it.

Natural amylin disappears from your bloodstream within minutes of being released, which is part of why its effect on appetite fades so quickly after a meal. Cagrilintide is an engineered version that lasts seven to eight days, and that's why you only need to inject basically once per week.

Amylin works in a completely different part of your brain than GLP-1. GLP-1 works in the hypothalamus, which sets your baseline drive to seek food between meals. Amylin works in the brainstem, in a region called the area postrema, which reads what is happening in your stomach right now.

The neurons that respond to Amylin don't even have GLP-1 receptors on them. A year of semaglutide does not wear out a receptor it never touched.

So why does adding cagrelitide to retitrutide make sense? Well, retitrutide is only 40% as strong at GLP-1. That's why you feel hungrier. GLP-1 turns down the thermostat so you're not thinking about food as much between meals, and amylin flips the satiety switch sooner once you have started. That's why the combination works better than either one alone.

In a phase two trial published in The Lancet in 2021, they studied 706 participants for 26 weeks. At the highest dose, the average weight loss was about 10.8%.

In the Redefine One trial published in the New England Journal of Medicine in 2025, they studied 3,417 adults for 68 weeks. The group that received Cagrasema, which is a 2.4 milligram of cagrelitide combined with 2.4 milligrams of semaglutide, lost an average of 20.4% of their body weight. Semaglutide alone was only about 16%. And more than half of the participants on Cagrasema lost 20% or more of their body weight.

Research: Giblin 2026 (Diabetes Obes Metab); Kanu 2025 (Diabetes Obes Metab); McGlone 2024 (Peptides).

References

Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. PMID 41090431. Backs: retatrutide as a triple agonist of the GIP, GLP-1 and glucagon receptors; the scale of the phase 3 program. https://doi.org/10.1111/dom.70209 https://pubmed.ncbi.nlm.nih.gov/41090431/

Kanu C, Boye KS, Poon JL, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025;27(12):6988-6998. PMID 40916752. Backs: reduced hunger and reduced tendency to overeat in humans (the intake side), correlated with weight reduction. https://doi.org/10.1111/dom.70097 https://pubmed.ncbi.nlm.nih.gov/40916752/

McGlone ER, Tan TM. Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot? Peptides. 2024;176:171219. PMID 38615717. Backs: glucagon increases energy expenditure and decreases hepatic fat (the output side); also the honest caveats the community inherits (gastrointestinal side effects, muscle mass, heart rate). https://doi.org/10.1016/j.peptides.2024.171219 https://pubmed.ncbi.nlm.nih.gov/38615717/